TransMedics Reports 20.7% Revenue Growth in Q2 2026, Net Income Declines

TransMedics Group, Inc. reported its financial results for the second quarter and first half of 2026, revealing a total revenue of $189.9 million for the three months ended June 30, 2026, a 20.7% increase from $157.4 million in the same period of 2025. For the first half of 2026, revenue reached $363.9 million, up from $300.9 million year-over-year. The company achieved a net income of $14.7 million for the second quarter, a decrease from $34.9 million in the prior year, and a net income of $22.0 million for the first half, down from $60.6 million in 2025. The decline in net income was attributed to increased operating expenses, particularly in research and development and selling, general, and administrative costs.

The company experienced significant changes in its cost structure, with total operating expenses rising to $89.5 million in the second quarter of 2026, compared to $60.0 million in the same quarter of 2025. This increase was driven by higher research and development costs, which surged to $31.6 million from $15.9 million, and selling, general, and administrative expenses, which rose to $57.8 million from $44.1 million. The increase in expenses reflects TransMedics' ongoing investment in product development and expansion of its operational capabilities.

Operationally, TransMedics reported a gross profit of $113.2 million for the second quarter, resulting in a gross margin of 60%, slightly down from 61% in the previous year. The company noted that the decrease in gross margin was primarily due to a higher mix of service revenue, which typically carries lower margins than product revenue. The company’s product revenue for the second quarter was $111.2 million, while service revenue was $78.8 million, indicating a growing reliance on its National OCS Program (NOP) for organ procurement and transplant logistics services.

As of June 30, 2026, TransMedics had total assets of $1.46 billion, up from $1.07 billion at the end of 2025, with cash and cash equivalents amounting to $472.7 million. The company’s liabilities also increased significantly, totaling $946.3 million, compared to $595.3 million at the end of the previous year. This rise in liabilities was largely due to the issuance of convertible senior notes and the establishment of finance lease liabilities related to a new headquarters facility in Somerville, Massachusetts.

Looking ahead, TransMedics anticipates continued growth in revenue driven by the expansion of its NOP and increased adoption of its Organ Care System (OCS) products. However, the company acknowledged the potential need for additional funding to support its growth initiatives, which may include equity offerings or debt financing. The management expressed confidence that its existing cash reserves would be sufficient to fund operations for at least the next 12 months, while also highlighting the uncertainties associated with market conditions and regulatory approvals that could impact future performance.